Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tramadol + ondansetron is a combination of two small molecule drugs, tramadol and ondansetron, sometimes co-administered in clinical settings. Tramadol is an analgesic with dual mechanisms of action as a μ-opioid receptor agonist and inhibitor of serotonin and norepinephrine reuptake, used for moderate to moderately severe pain. Ondansetron is a selective 5-HT3 (serotonin) receptor antagonist primarily used as an antiemetic to prevent nausea and vomiting. When administered together, there is evidence that ondansetron can reduce the analgesic efficacy of tramadol by antagonizing spinal 5-HT3 receptors involved in pain modulation. Additionally, this combination increases the risk for serotonin syndrome and cardiac arrhythmias such as QT prolongation; thus, their concurrent use should be approached with caution or avoided unless specifically indicated[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol + ondansetron.